Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naive Fit Patients With CLL Without TP53 Aberrations. Ehlers LH, Levin MD, van der Klift M, Jensen MB, et al. Eur J Haematol 2026;116:873-882.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ehlers LH, Levin MD, van der Klift M, Jensen MB, et al. Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naive Fit Patients With CLL Without TP53 Aberrations. Eur J Haematol 2026;116:873-882.
PMID: 41740591